⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12386581 | 0.74 | — | — | |
| SCHEMBL13323568 | 0.71 | — | — | |
| SCHEMBL14397335 | 0.70 | — | — | |
| SCHEMBL840077 | 0.70 | PSMD14 (0.44) | — | |
| SCHEMBL12040071 | 0.70 | — | — | |
| SCHEMBL12726470 | 0.67 | TSHR (0.33) | — | |
| SCHEMBL20154126 | 0.65 | — | — | |
| SCHEMBL24125191 | 0.61 | CREBBP (0.57) | — | |
| SCHEMBL14622471 | 0.61 | CA2 (0.67) | — | |
| SCHEMBL16601566 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3456310-A1 | IMPROVED GLOSS LIP BALM FORMULATION | Mast Industries (Far East) Limited (HK) | 2019-03-20 | — | — | EP | disclosed |
| US-8815903-B2 | Indole derivative and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8796247-B2 | Indole derivative, and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20140128408-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140018335-A1 | INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20110257145-A1 | METHOD OF TREATING NEUROLOGICAL DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |